The Technical Analyst
Gossamer Bio Inc [GOSS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Gossamer Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-5.21% $0.743
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 167.61 mill |
| EPS: | -1.180 |
| P/E: | -0.630 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 225.58 mill |
| Avg Daily Volume: | 1.307 mill |
| RATING 2024-04-22 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.630 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.630 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.629 - 0.857 ( +/- 15.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-27 | Christian Waage | Sell | 6 430 | Common Stock |
| 2024-03-27 | Giraudo Bryan | Sell | 6 430 | Common Stock |
| 2024-03-27 | Hasnain Faheem | Sell | 23 172 | Common Stock |
| 2024-03-18 | Aranda Richard | Sell | 4 018 | Common Stock |
| 2024-03-18 | Peterson Caryn | Sell | 4 018 | Common Stock |
| INSIDER POWER |
|---|
| 76.09 |
| Last 96 transactions |
| Buy: 11 435 031 | Sell: 1 983 654 |
Forecast:
16:00 - $0.743
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.743
Forecast 2: 16:00 - $0.743
Forecast 3: 16:00 - $0.743
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.743 (-5.21% ) |
| Volume | 1.296 mill |
| Avg. Vol. | 1.307 mill |
| % of Avg. Vol | 99.15 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GOSS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.846 | N/A | Active |
|---|
GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Latest Press Releases
2024-03-12 07:31:00 - Press Release
Gossamer Bio Announces Appointment Of Steven D. Nathan, M.d.
San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced the appointment of steven d. nathan, m.d., and skye drynan to its board of directors. dr. nathan is medical director of inova's advanced lung disease program and lung transpla.
2024-03-05 07:31:00 - Press Release
Gossamer Bio Announces Fourth Quarter And Full-year 2023 Financial Results And Provides Business Update
San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced its financial results for the fourth quarter and year ended december 31, 2023, and provided a business update. “we were thrilled to enroll the first patient in the registrational prosera study last year, and we are pleased with the pace of site activati.
2024-01-08 16:01:00 - Press Release
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced that the compensation committee of gossamer's board of directors approved the grant, effective january 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the company's com.
2023-12-13 16:01:00 - Press Release
Gossamer Bio To Host Webcast To Discuss Latest Seralutinib Open-label Extension Data On December 18, 2023
San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced that it will host a public conference call and webcast for investors and analysts on monday, december 18, 2023 at 8:30 am et to discuss the latest seralutinib clinical data from the ongoing torrey phase 2 open-label extension study in pah patients. sera.
2023-12-05 16:01:00 - Press Release
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced that it has granted stock options to bob smith, gossamer's newly appointed chief commercial officer. the compensation committee of gossamer's board of directors approved the grant, effective december 4, 2023, to mr. smith of a stock option to purchase 1.
Latest News
2024-03-07 10:56:12 - Zacks Investment Research
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
2024-03-05 22:52:59 - InvestorPlace
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
Gossamer Bio (NASDAQ: GOSS ) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.
2024-01-31 14:23:57 - InvestorPlace
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you're not going to get rich off of them.
2023-12-13 16:01:00 - Business Wire
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Sera.
2023-11-17 13:32:10 - PennyStocks
11 Top Penny Stocks To Buy Now According To Insiders
Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.
2023-11-15 12:52:53 - PennyStocks
5 Penny Stocks To Buy Now According To Insiders
Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
2023-09-07 07:44:00 - Business Wire
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Profes.
2023-07-27 15:04:00 - Proactive Investors
Gossamer Bio stock struggles from lack of near-term catalysts: analysts
Shares of Gossamer Bio fell Thursday, and the company earned a downgrade from analysts at UBS. Citing a "lack of near-term catalysts," the firm downgraded the biopharmaceutical company to Neutral from Buy and slashed its price target to $1.25 from $8.
2023-07-24 16:16:00 - Business Wire
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT. Gossamer's management team will be joined by world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White to discuss the upcoming P.
2023-04-02 04:12:42 - Seeking Alpha
Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib
Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vascular resistance, 6-minute walk distance, and NT-proBNP levels. Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations, and is moving forward with a revised Phase 3 trial.